Curated News
By: NewsRamp Editorial Staff
October 05, 2026
NanoViricides Advances Oral Ebola Treatment to Phase II Trial in DRC
TLDR
- NanoViricides advances NV-387 oral gummies into Phase IIA for Ebola, positioning itself in the antiviral market.
- Phase IIA identifies optimal dosing before Phase IIB, evaluating NV-387's efficacy against Bundibugyo Ebolavirus.
- NanoViricides' oral Ebola treatment could be deployed in resource-limited settings, improving global health access.
- NV-387 is a dissolvable oral gummy that requires no water, simplifying Ebola treatment in remote areas.
Impact - Why it Matters
This news matters because it represents a potential breakthrough in the fight against Ebola, a highly lethal virus that has caused devastating outbreaks in resource-limited regions. An oral antiviral that is easy to administer could dramatically improve treatment accessibility and speed up response times during outbreaks, ultimately saving lives. Moreover, NanoViricides’ broad-spectrum approach could lead to therapies for other viral threats, addressing significant unmet medical needs. Investors and public health officials should monitor this trial closely, as positive results could mark a major advancement in antiviral therapy and validate the company’s innovative nanoviricide platform.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has shared new details about its Phase II clinical trial of NV-387 Oral Gummies for treating the Bundibugyo Ebolavirus (BDBV) outbreak and other Ebola viruses in the Democratic Republic of Congo. Enrollment for Phase IIA is set to begin on or about September 23, 2026, following the trial’s designed protocol. This initial stage aims to identify an optimal, well-tolerated dosing regimen and will serve as a go/no-go decision point before proceeding to Phase IIB, a randomized controlled trial that will evaluate the drug’s efficacy. The company emphasizes that NV-387 is designed to attack the virus and reduce viral load, offering a novel approach to combating Ebola.
NV-387 is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort, making it potentially ideal for deployment in resource-limited settings. NanoViricides characterizes NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses, providing a rationale for potential activity against Bundibugyo and other Ebola strains. The company’s broader pipeline includes NV-387 as a lead candidate for respiratory viral infections such as RSV, COVID, Long COVID, Influenza, and MPOX/Smallpox, as well as NV-HHV-1 for Shingles. NanoViricides is also developing drugs against Herpes, HIV, Hepatitis C, Rabies, Dengue, and other viral diseases, leveraging its nanoviricide technology licensed from TheraCour Pharma. For more details, the full press release is available at https://ibn.fm/zjg8X.
BioMedWire, a specialized communications platform focused on biotechnology and life sciences, distributed this news. As part of the Dynamic Brand Portfolio @ IBN, BioMedWire provides access to wire solutions, editorial syndication, and social media distribution to help companies reach a wide audience. The latest updates on NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances Oral Ebola Treatment to Phase II Trial in DRC
